Hollings Headlines // November 2019
Dr. Pastis
New device debuts fighting No. 1 cancer killer

A new robotic bronchoscopy system now available at MUSC Health is the only one of its kind in the state, and it’s just in time for this year’s Lung Cancer Awareness Month. Dr. Nick Pastis says it’s meant to be used in patients who have lung nodules and are at increased risk of having cancer.

LOWVELO recap
Riders revel in the ride

Listen to these riders' inspiring words and relive #LOWVELO19 through the latest video that captures the experience from a wide range of participants from one of the ride’s youngest riders – age 15 – to its oldest – 79.

Marlon Kimpson and staff
Shine a light on lung cancer

Hollings Cancer Center hosted Shine a Light on Lung Cancer on Nov. 19. It was a fun filled evening of awareness that included our multidisciplinary team reenacting a tumor board session and guest speakers sharing their inspiring stories. It was a wonderful opportunity to support and honor patients and survivors, connect with the community and help make a difference.

State Sen. Marlon Kimpson, who was in attendance, says, "I think what distinguishes this center is that they are doing clinical studies. I can only imagine when you are diagnosed with what may be a life ending illness, you want the benefit of people doing cutting-edge work in this area. And we ought to applaud the doctors and staff at the Hollings Cancer Center for doing this work for South Carolinians and people across the nation."

Dr. Lewis
Subscribe for a free issue of MUSC Hollings Horizons magazine or check out the digital version . You also can get the latest patient stories and clinical and research updates on our Hollings News site .
Research
Dr. Hughes-Halbert
Funding renewed for Hollings program to enroll more patients to clinical trials

A $5.3 million National Cancer Institute (NCI) grant renewal allows Hollings Cancer Center program to be able to enroll more rural and underserved cancer patients into clinical trials.

Dr. Thaxton lab
Researcher on winning team at renowned immunotherapy event

Hollings researcher Dr. Jessica Thaxton's team, SITcure, was named the winner of the 2018 Society for Immunotherapy Cancer's Sparkathon. “We came up with the idea to run a randomized clinical trial in order to determine when it is safe to take a patient off of immunotherapy,” Thaxton says. “The reason that this is even a Sparkathon-worthy idea is because we are proposing to take patients off of immunotherapy prior to what the current guidelines say.”

Dr. Williams
New insights into target for cancer therapeutics

MUSC researchers report in Nature Communications that they have obtained 3D structural snapshots of Cdc34 in action. “I chose to focus on Cdc34 first because of its clinical relevance,” said Katelyn Williams, first author of the published research. “My clinical interest is pediatric hematology/oncology, and Cdc34 is a crucial regulator of many biological processes and functions abnormally in many cancers.”

Drs. Oleinik and Ogretmen
Newly discovered protein is the permit to the powerhouse of cells

A team of investigators at MUSC has recently characterized a novel player in aging pathways, a protein that they call P17/PERMIT. This finding could provide critical insights into age-related diseases such as cancer and Alzheimer’s. The team, led by Dr. Besim Ogretmen, reported its findings in the September 2019 issue of Science Advances.

86 Jonathan Lucas Street, Charleston, SC 29425 | Privacy Policy
Connect With Us